###begin article-title 0
Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01</italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
We evaluated the significance of the genes, defined as DRB1*04 or DRB1*01, in rheumatoid arthritis (RA) patients. We focused on the role of genetic and serologic markers to predict disease activity and destructive process of joints.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
Sixty patients with RA were examined. Radiographic changes were evaluated by (Larsen score) and disease activity was measured by disease activity score 28 (DAS28). The markers analyzed were: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-cyclic citrullinated peptides (anti-CCP2) and HLA-DRB1 alleles typed by PCR.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 248 258 248 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1* 0405</italic>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 434 442 434 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 650 657 650 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04</italic>
###xml 663 670 663 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01</italic>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
In this study, anti-CCP antibodies, CRP, RF and AKA were detected in 83.3%, 56.7%, 71.7% and 52% of patients respectively. HLA-DRB1*01 was found in 45% of patients and 35% of them had one or two HLA-DRB1*04 alleles. According to DRB1*04 subtypes, (DRB1* 0405) was present in of 80% them. For prediction of grade of activity, the independent predictors were anti-CCP (OR 19.6), and DRB1*04 positive allele (OR 5.1). The combination of DRB1*04 + anti-CCP antibodies gave increase in the specificity and positive predictive value to 92% and 90 respectively. As regards to the prediction of radiological joint damage, the independent predictors were HLA-DRB1*04, HLA-DRB1*01, RF, and CRP > 18 (OR 5.5, 4.5, 2.5, 2.0 respectively).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our findings suggest that anti-CCP2 is superior to RF for the detection of RA and provided predictive information on joint destruction and disease activity. The presence of RA associated antibodies (ACCP or RF) and/or the SE genes are indicative for a poorer radiological outcome and higher grade of activity.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 505 510 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 469 474 <span type="species:ncbi:9606">human</span>
Rheumatoid arthritis (RA) is an inflammatory disease of unknown cause. The course of rheumatoid arthritis is ranging from mild to aggressive forms, the latter being very difficult to cope with. It has been shown that early diagnosis and treatment reduce joint destruction, and improve survival [1]. Risk factors have been identified in groups of patients with different outcomes such as baseline radiographic joint changes, presence of rheumatoid factor (RF), specific human leukocyte antigens (HLA); HLA-DRB1 genotypes, high disease activity, high disability scores, and high levels of acute phase proteins [2]. Antibodies to cyclic citrullinated peptide (anti-CCP) have been documented extensively over recent years as highly specific serological markers for rheumatoid arthritis, with important clinical implications for diagnosis and prognosis [3].
###end p 11
###begin p 12
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
It has been suggested that the etiology of RA is due to an interaction between genetic and environmental factors. Genetic studies have demonstrated multiple HLA-DRB1 alleles encoding a conserved sequence at amino acid positions 70-74 are associated with susceptibility and severity of RA. This conserved sequence is commonly known as the shared epitope (SE). The role of the SE in the evolution of articular destruction has yielded conflicting results [4,5].
###end p 12
###begin p 13
###xml 123 131 123 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04</italic>
The present study is a cross-sectional analysis aimed to evaluate the significance of the presence of SE genes, defined as DRB1*01 or DRB1*04, in relation to anti-CCP antibodies, antikeratin antibody (AKA) and RF in individuals who developed RA. We focused on disease activity and joint damage, evaluated on radiographs, as outcome variables.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 805 806 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 948 949 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1043 1044 1043 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">Patients</span>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
This study was carried out on 60 outpatients who fulfilled the American college of rheumatology criteria for RA. A written consent was obtained from the patients according to the Declaration of Helsinki prior to enrollment in the study. The study was approved by the Assiut University local ethical committee. Patients were subsequently treated with disease modifying antirheumatic drugs (usually methotrexate, sulphasalazine, or a combination of both). The patients were evaluated for age; sex; body mass index; disease duration; duration of morning stiffness; patients' assessment of pain (on a visual analogue scale); number of swollen and tender joints, disease activity score; presence or absence of nodules and extra-articular manifestations. Disease activity by the disease activity score (DAS28) [6]. Global health and pain and visual analogue scale were assessed. Functional disability was evaluated using health assessment questionnaire [7]. Hand, wrist, and foot radiographs were obtained, evaluated and scored using Larsen method [8].
###end p 15
###begin title 16
Sample handling and investigations
###end title 16
###begin p 17
Blood samples were collected; for complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and DNA isolation. One hundred samples were taken from healthy blood donors as a control for HLA typing; twenty of them were used for serologic markers.
###end p 17
###begin title 18
Determination of antibodies
###end title 18
###begin p 19
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 433 436 <span type="species:ncbi:9685">Cat</span>
###xml 680 683 <span type="species:ncbi:10116">rat</span>
RF was detected by the kit supplied Biotec Laboratories Lot No. RF -460 based on agglutination test using particles sensitized with human IgG. ANA was detected by the Fluro-kit supplies by supplied by DiaSorine Catalog No 1740 based on indirect immunoflorescent for the screening and titration of antinuclear antibodies (ANA). Anti-CCP2 antibodies were detected by enzyme-linked immunosorbent assay Kit supplies by INOVA Diagnostica Cat. NO 570139. Serum samples with a test result 25 U/ml were considered positive, and designated as the "standard" cut off. AKA was detected by kit supplied by IMMECO Diagnostic, Lot No. 2120-8, based on indirect immunofluorescence antibodies on rat esophagus substrate.
###end p 19
###begin title 20
HLA-DRB1 genotyping
###end title 20
###begin p 21
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 172 181 172 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1072 1076 1072 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 1098 1105 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01</italic>
###xml 1107 1111 1107 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 1112 1114 1112 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">02</italic>
###xml 1141 1150 1141 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1-0404</italic>
###xml 1152 1161 1152 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1-0405</italic>
###xml 1181 1185 1181 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 1237 1255 1237 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0409,*0413, *0416 </italic>
###xml 1260 1265 1260 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0421 </italic>
###xml 1285 1290 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401 </italic>
###xml 1300 1304 1300 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0408</italic>
###xml 1307 1312 1307 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0410 </italic>
###xml 1317 1322 1317 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0419 </italic>
###xml 1342 1346 1342 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0404</italic>
###xml 1352 1362 1352 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 1416 1424 1416 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1451 1459 1451 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1475 1476 1475 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
HLA typing was performed using sequence specific oligonucleotide technique, reversed dot blot hybridization technique (Dynal RELI HLA-DRB1, product No.802.01) [9]. DNA for HLA-DRB1 typing of patients was isolated from peripheral blood mononuclear cells by using the DNA Isolation Kit (QIAamp minikit, Qiagen, Hilden, Germany). The biotinylated primers anneal to their target, Tag DNA polymerase extend the annealed primers along the target templates to produce a biotinylated DNA sequence (amplicon). After polymerase chain reaction amplification, the amplicons are chemically denatureated, theses are added to nylon membrane that contains an array of immobilized sequence specific oligonucleotide probes that contain a complementary target sequence and thus are captured onto the membrane strip. The amplicon-probe complex is visualized using a colorimetric reaction. The resulting probe signals are captured to the control probe intensity and the samples recoded for interpretation [10]. The specificity of the amplification can be locus specific (eg, HLA-A, HLA-B, HLA-DRB1) group specific (eg, DRB1*01, DRB1*02), or allele-specific (eg, DRB1-0404, DRB1-0405). According to HLA-DRB1*04 subtyping the shared epitopes encoding alleles *0409,*0413, *0416 and *0421 were classified as *0401 alleles, *0408, *0410 and *0419 were classified as *0404. The DRB1*0405 alleles were analyzed as a separate entity. All other DRB1*04 alleles were classified as DRB1*04 non-SE alleles [4].
###end p 21
###begin title 22
Statistical analysis
###end title 22
###begin p 23
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 726 728 726 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 508 511 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
Statistical analyses were done using SPSS 15 statistical software (SPSS Inc, Chicago, Illinois, USA). Continuous variables were transformed into categorical variables using the median value as the cut off point. Comparison of categorical variables between groups, as well as univariate analysis of the relation between all baseline values and the outcome measure was undertaken using the X2 test, with Fisher's exact correction when appropriate. Sensitivity and specificity, and negative (NPV) and positive (PPV) predictive values of the possible predictors were calculated. Significant univariate variables were included in a multivariate stepwise logistic regression model to find relevant independent prognostic variables. P value < 0.05 is considered significant.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 125 130 <span type="species:ncbi:9606">women</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
Clinical and laboratory investigations were illustrated in Table 1. The median age of the patients was 50 years and 90% were women. According the positivity of anti-CCP antibodies, 50 (83.3%) patients were anti-CCP antibodies positive. CRP, RF and AKA were detected in 34 (56.7%), 43 (71.7%) and 31 (52%) of patients respectively.
###end p 25
###begin p 26
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Clinical and laboratory characteristics of patients
###end p 26
###begin p 27
###xml 226 231 <span type="species:ncbi:9606">human</span>
Values are expressed as n (%). AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides antibodies; ANA: antinuclear antibodies; DAS: disease activity score; CRP: C-reactive protein; RF: rheumatoid factor; HLA: human leukocyte antigen. * Cut-off values are medians.
###end p 27
###begin p 28
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Comparing anti-CCP positive with anti-CCP negative patients (Table 1); anti-CCP positive patients had a significantly higher frequency of high ESR, RF, ANA and AKA (P = 0.04, 0.02, 0.03 and 0.05) respectively.
###end p 28
###begin p 29
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 149 175 149 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01, DRB1*02, DRB1*04 </italic>
###xml 196 198 196 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 261 269 261 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 308 316 308 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
The frequencies of HLA-DRB1 alleles in patients and control are shown in Table 2. There was a statistically significant increase in the frequency in DRB1*01, DRB1*02, DRB1*04 compared to control (P = 0.001, 0.05 and 005 respectively). In this study 45% had HLA-DRB1*01 and 35% of patients had one or two HLA-DRB1*04 alleles.
###end p 29
###begin p 30
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Frequencies of HLA-DRB1 alleles in patients and control
###end p 30
###begin p 31
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0409</italic>
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0413</italic>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0416 </italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0421 </italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0401 </italic>
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0408</italic>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0410 </italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0419 </italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0404</italic>
###xml 251 261 251 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 315 323 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 350 358 350 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 373 376 373 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">(4)</sup>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Values are expressed as n (%). HLA: human leukocyte antigen. *According to HLA-DRB1*04 subtyping the shared epitopes encoding alleles *0409, *0413, *0416 and *0421 were classified as *0401 alleles, *0408, *0410 and *0419 were classified as *0404. The DRB1*0405 alleles were analyzed as a separate entity. All other DRB1*04 alleles were classified as DRB1*04 non-SE alleles.(4)
###end p 31
###begin p 32
###xml 40 50 40 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1* 0405</italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 121 129 121 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 215 217 215 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
It was found that RF associated allele (DRB1* 0405) was present in of 80% of DRB1*04 positive patients. "Double dose" of DRB1*04 (homozygous) was found in 8/60 (13%) of our patients versus 3/100 (3%) in the control P = 0.05 (Data is not shown in the table).
###end p 32
###begin title 33
Predictors of the disease activity grade
###end title 33
###begin p 34
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 241 249 241 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 304 312 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 506 514 506 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 576 578 576 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 747 755 747 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 371 374 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
Univariate predictors of the grade of disease activity were summarized in Table 3. Anti-CCP had the highest sensitivity; 97%, and NPV 90%. On multivariate analysis, the independent predictors of disease activity were anti-CCP (OR 19.6), and DRB1*04 positive allele (OR 5.1). (Table 4) The combination of DRB1*04 + anti-CCP antibodies gave increase in the specificity and PPV to 92% and 90%, with a sensitivity and NPV of 42% and 41% respectively. The presence of single and double gene carriage of the HLA-DRB1*04 resulted in a significantly higher grade of disease activity (P = 0.009) compared with its absence. With regard to a possible gene dosage effect, no statistically significant difference between double and single gene carriage of the DRB1*04 was observed (data is not shown in tables).
###end p 34
###begin p 35
Univariate predictors of disease activity grade
###end p 35
###begin p 36
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 200 203 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides antibodies; ANA: antinuclear antibodies; CRP: C-reactive protein; HLA: human leukocyte antigen; NPV: negative predictive value; PPV: positive predictive value; RF: rheumatoid factor
###end p 36
###begin p 37
Multivariate predictors of disease activity grade
###end p 37
###begin p 38
###xml 62 67 <span type="species:ncbi:9606">human</span>
Anti-CCP: anti-cyclic citrullinated peptides antibodies; HLA: human leukocyte antigen, OR: Odds ratio; CI: confidence interval.
###end p 38
###begin title 39
Predictors of radiological joint damage
###end title 39
###begin p 40
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04</italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01</italic>
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
ESR first hour > 32 had the highest sensitivity 98%, and NPV 93% (Table 5). In multivariate analysis, the independent predictors were HLA-DRB1*04, HLA-DRB1*01, CRP > 18, and RF (Table 6).
###end p 40
###begin p 41
Univariate predictors of radiological joint damage (Larsen score)
###end p 41
###begin p 42
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 200 203 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides antibodies; ANA: antinuclear antibodies; CRP: C-reactive protein; HLA: human leukocyte antigen; NPV: negative predictive value; PPV: positive predictive value; RF: rheumatoid factor.
###end p 42
###begin p 43
Multivariate predictors of radiological joint damage (Larsen score)
###end p 43
###begin p 44
###xml 53 58 <span type="species:ncbi:9606">human</span>
CRP: C-reactive protein; RF: rheumatoid factor; HLA: human leukocyte antigen; OR: Odds ratio; CI: confidence interval.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1151 1153 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Anti-CCP-antibody is a synthetic cyclic peptides containing citrulline. It is incorporated into newly proposed diagnostic criteria for rheumatoid arthritis, with higher sensitivity. The high predictive value of anti-CCP antibodies is indicating that citrullination and production of anti-CCP antibodies and RF are early processes in the development of RA [11]. The present work revealed strong complementarities of RF to anti-CCP as 65% patients lacking RF found to be positive for anti-CCP. Some reports suggest that RF and anti-CCP should be combined to reach optimum diagnostic properties [12]. Discrepancy can be explained by the fact that in the literature stratification for specificity was not performed, and therefore, the results of different studies are not comparable [13]. The frequencies of ANA and AKA were 36%, 52% respectively which indicate that testing for this spectrum of auto antibodies carries little advantage over RF or anti-CCP in diagnosing RA. A significant association of AKA with Anti-CCP may relate to that citrulline (profilaggrin) appears to be an essential constituent of the antigenic determinants recognized by AKA [14].
###end p 46
###begin p 47
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
In the present work, the sensitivity of anti-CCP was significantly higher than that of the RFs for prediction of grade of disease activity. This findings were supported by the data previously published [1,15].
###end p 47
###begin p 48
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
It was reported that anti-CCP is an important predictor of radiological outcome. Preventing and diminishing joint damage is an important treatment goal in early rheumatoid arthritis [1].
###end p 48
###begin p 49
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
According the prediction models reported by, Combe et al [2], for instance, variables reflecting disease activity also contribute to the prediction of joint damage. In this study, anti-CCP gave statistically significant differences between the positive and negative group with radiological damage. These data are comparable with the findings of other groups using a similar approach [15-17]. In our study serum anti-CCP added some prognostic information to ESR, CRP and RF, and it was the most sensitive predictor of joint damage, following ESR. These findings were in agreement with earlier reports [4], but other studies mentioned that anti-CCP was the only significant predictor, together with C reactive protein [18]. Vencovsky et al reported that the combination RF, CRP and anti-CCP2 antibodies revealed 10 times higher radiological damage [17] and early erosions [19]. However it was needed to be emphasized that the results based on dichotomization not useful in everyday clinical practice. So, we investigated whether appropriate cut off could be determined to identify those patients with the most aggressive radiological course.
###end p 49
###begin p 50
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 181 189 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 193 201 193 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 746 761 746 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401/0101 </italic>
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1709 1711 1709 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 824 839 <span type="species:ncbi:10090">transgenic mice</span>
Genetic studies have demonstrated that HLA alleles have been implicated in a number of chronic inflammatory diseases. RA has been associated with the SE of HLA-DRB1, which includes DRB1*04 and DRB1*01 alleles [19]. In the present study we found a discrepant relationship between RF and anti-CCP2 with the presence of the SE gene. Also our results do not support the opinion that there is a direct association between SE gene carriage and the occurrence of antibodies directed to CCP (or RFs) leading to the development of RA, but rather suggest that there is a synergistic interaction between these factors. In contrast Berglin et al reported that patients with early RA, had significant association between anti-CCP antibodies and expression of DRB1*0401/0101 [5]. The conversion of arginine to citrulline in HLA-DRB1*0401 transgenic mice has been demonstrated to significantly increase activation of CD4+ T cells [20], so that individuals carrying the SE genes may have more sustained T- and B-cell responses to citrullinated antigens than non carriers [13]. The presence of citrulline within the HLA binding peptide enhances the peptide-MHC affinity and leads to the activation of CD4+ T cells during presentation of citrullinated antigens [20]. This specific T-cell dependent immune response to citrullinated peptides may contribute to the occurrence of RA. A quite contradictory suggestion is that HLA antigens do not predispose to the autoimmune disease per se but rather fail to provide protection. Abnormal T-cell regulation associated with certain HLA haplotypes leads to the loss of self-tolerance followed by polyclonal activation of T and B cells and the subsequent production of auto antibodies [21].
###end p 50
###begin p 51
###xml 102 110 102 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 114 122 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 159 167 159 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 481 489 481 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
In the present work there was a statistically significant difference observed between carriage of the DRB1*04 and DRB1*01 alleles with radiological damage and DRB1*04 with disease activity, these findings were in agreement with those previously reported [13,17]. Recent genome wide scanning studies using micro satellite loci have confirmed that there is strong linkage between this region with susceptibility and severity of RA [22,23]. Moreover Petersson et al [4] reported that DRB1*04 SE double gene dose is associated with disease severity in RA. In contrast Eberhardt et al [24] did not find the genotypes to be strongly associated with disease severity after two and five years.
###end p 51
###begin p 52
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 241 249 241 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 351 359 351 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 474 482 474 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 684 694 684 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401 </italic>
###xml 706 716 706 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1350 1358 1350 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 1261 1269 <span type="species:ncbi:9606">patients</span>
###xml 1431 1439 <span type="species:ncbi:9606">patients</span>
The role of the SE in the evolution of articular destruction has yielded conflicting results; however, in most studies the presence of the SE is associated with increased joint destruction [14,22]. Others revealed an association between HLA-DRB1*04 and erosive disease [25], Goronzy et al [25], and Petersson et al [4] considered homozygosity for HLA-DRB1*04 as a major predictor of the development of erosions. In Caucasians of Northern European origin, the double dose of DRB1*04 SE alleles (0401/0401 genotype) was associated with radiographic signs of progressive joint damage [26]. A strong concordance was revealed between our study and that in East Asian populations, in which DRB1*0401 is rare and DRB1*0405 is the most frequent RA associated HLA-DRB1 genotype. The latter allele has also been reported to be associated with an increased risk for extra-articular manifestations of RA [27]. In contrast, others reported that the presence of shared epitope in single or double dose did not provide any predictive information on the development of joint damage and was not related to functional outcome [28]. In another study, by Mattey et al [16], reported that a predictive value of shared epitopes for radiological changes was restricted to RF negative patients. These discrepancies may reflect variability in the relative frequencies of HLA-DRB1*04 in different populations. Possibly, further studies on larger numbers of patients might solve this issue.
###end p 52
###begin p 53
###xml 66 75 66 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR-B1*04 </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
In the Present work the combination between anti-CCP, and the HLA-DR-B1*04 gave more identification of the grade of disease activity than a single test alone. The presence of RF, the SE, and anti-CCP2 antibodies yielded a 10 times higher average expectancy rate for a high radiological progression rate compared with the absence of the three parameters [15,16].
###end p 53
###begin title 54
Conclusion
###end title 54
###begin p 55
Anti-CCP2 is superior to RF for the detection of RA and provided predictive information on joint destruction and disease activity. The presence of RA associated antibodies and/or the SE genes are indicative for a poorer radiological outcome and higher grade of activity. Thus, we shall need new strategies, both in research and in clinical practice, where we may now possess a new means for analyzing the risk of RA in individuals who will have different needs to acquire such information.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The authors declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
NAF participated in study design, data acquisition and critical manuscript revision. AME-E participated in study design, performing laboratory investigations other than HLA, and critical manuscript revision. EM participated in study design, HLA analysis, analysis and interpretation of data, performed the statistical analysis, wrote the manuscript, and performing manuscript drafting and submission. RMB participated in study design, HLA analysis, analysis and interpretation of data, and critical manuscript revision. HBH participated in HLA analysis and manuscript revision. SA participated in study design, data acquisition, and critical manuscript revision. MM participated in study design and data acquisition. H-AGR participated in laboratory investigations other than HLA and manuscript revision. FA participated in study design, data acquisition, and critical manuscript revision. All authors read and approved the final manuscript.
###end p 59
###begin article-title 60
BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)
###end article-title 60
###begin article-title 61
Prognostic factors for radiographic damage in early rheuma-toid arthritis: a multiparameter prospective study
###end article-title 61
###begin article-title 62
Prognostic laboratory markers of joint damage in rheumatoid arthritis. Prognostic laboratory markers of joint damage in rheumatoid arthritis
###end article-title 62
###begin article-title 63
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis
###end article-title 63
###begin article-title 64
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis
###end article-title 64
###begin article-title 65
DAS-Score.NL
###end article-title 65
###begin article-title 66
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Assessing disability in patients with rheumatoid arthritis
###end article-title 66
###begin article-title 67
Radiographic evaluation of rheumatoid arthr-itis and related conditions by standard reference
###end article-title 67
###begin article-title 68
Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes
###end article-title 68
###begin article-title 69
###xml 42 72 42 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A, -B, -C, -DRB1/3/4/5, -DQB1 </italic>
###xml 133 156 133 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A, -B, -C, -DR and -DQ </italic>
The HLA dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens
###end article-title 69
###begin article-title 70
Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis
###end article-title 70
###begin article-title 71
Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for anti-filaggrin autoantibody detection by line imm-unoassay
###end article-title 71
###begin article-title 72
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset
###end article-title 72
###begin article-title 73
High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritisScand
###end article-title 73
###begin article-title 74
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis
###end article-title 74
###begin article-title 75
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 </italic>
Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis
###end article-title 75
###begin article-title 76
Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis
###end article-title 76
###begin article-title 77
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations
###end article-title 77
###begin article-title 78
The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
###end article-title 78
###begin article-title 79
###xml 147 157 147 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401 </italic>
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule
###end article-title 79
###begin article-title 80
HLA association with autoimmune disease: a failure to protect
###end article-title 80
###begin article-title 81
From proteomics to molecular epidemiology: relevance of autoantibodies
###end article-title 81
###begin article-title 82
Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families
###end article-title 82
###begin article-title 83
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB </italic>
Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis
###end article-title 83
###begin article-title 84
Prognostic markers of radiographic progression in early rheumatoid arthritis
###end article-title 84
###begin article-title 85
Predictors of extra-articular manifestations in rheumatoid arthritis
###end article-title 85
###begin article-title 86
###xml 19 29 19 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
Association of HLA-DRB1*0405 with extra-articular manifestations and erosions in Singaporean Chinese with rheumatoid arthritis
###end article-title 86
###begin article-title 87
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage
###end article-title 87

